Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PWRM.OB, DMED, DHI, DAKT - Stock Alerts! from CRWEfinance.com - , Power3 Medical Products, D. Medical Industries Ltd., D.R. Horton, Inc.,and Daktronics, Inc.

crwefinancelogo2

signup3m

Power3 Medical Products, Inc. (OTC:PWRM)

PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, PWRM's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of PWRM, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."

"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.

PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.

To learn more about PWRM visit: http://www.Power3Medical.com

*********************

D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMDC)("D. Medical"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced recently, the execution of a distribution agreement with Pharmaserve-Lilly S.A.C.I. ("Pharmaserve-Lilly") for the distribution of its ADI durable insulin pump, related consumables and its Universal Detach Detect Infusion Sets in Greece.

D. Medical is a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps.

*********************

D.R. Horton, Inc. (NYSE:DHI), America’s Builder, preveiously announced that the Company will release earnings for its fourth quarter and fiscal year ended September 30, 2010 on Friday, November 12, 2010 before the market opens. The Company will host a conference call on that morning at 10:00 a.m. Eastern Time (NYSE:ET). The dial-in number is 877-407-8033. Participants are encouraged to call in five minutes before the call begins (9:55 a.m. ET). Please reference the call host, Donald J. Tomnitz, CEO of D.R. Horton, Inc. The call will also be webcast from the Company’s website at www.drhorton.com on the “Investors” page.

D.R. Horton, Inc., America’s Builder, is the largest homebuilder in the United States, based on its 21,404 homes closed in the twelve-month period ended June 30, 2010. Founded in 1978 in Fort Worth, Texas, D.R. Horton has operations in 72 markets in 26 states in the East, Midwest, Southeast, South Central, Southwest and West regions of the United States. The Company is engaged in the construction and sale of high quality homes with sales prices ranging from $90,000 to over $700,000. D.R. Horton also provides mortgage financing and title services for homebuyers through its mortgage and title subsidiaries.

*********************

Daktronics, Inc. (Nasdaq:DAKT) recently announced that its Board of Directors approved a special cash dividend of $0.50 per share of common stock.

"Given our cash position of more than $70 million as of the end of the first quarter of fiscal 2010 and our belief that we can continue to generate free cash flow from the business over the long term, we felt it was appropriate to return a portion of this cash to shareholders in the form of a special dividend," said Jim Morgan, president and chief executive officer. "We maintain sufficient cash reserves to fund our current initiatives and working capital needs over the foreseeable future."

Daktronics has strong leadership positions in, and is one of the world's largest suppliers of electronic scoreboards, computer-programmable displays, large screen video displays and control systems. The Company excels in the control of large display systems, including those that require integration of complex multiple displays showing real-time information, graphics, animation and video. Daktronics designs, manufactures, markets and services display systems for customers around the world, in sport, business and transportation applications.

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).